Middle East and Africa Underactive Bladder Market – Industry Trends and Forecast to 2029

Middle East and Africa Underactive Bladder Market Analysis and Insights

Middle East and Africa underactive bladder market is driven by the factors such as rising incidences of neurogenic bladder infections, increasing research funding, development of novel therapies for Underactive Bladder (UAB), and pipeline products enhancing its demand along with rising investment in R&D leading to market growth. Currently, healthcare expenditure has increased across developed and emerging countries which is expected to create a competitive advantage for manufacturers to develop new and innovative products. Additionally, the surge in healthcare expenditure and increase in the prevalence of bladder disorders positively affect the market.

However, the high cost of treatment restricts patients to accommodate high-quality and effective solutions. Henceforth, the high cost of treatment procedures negatively impact the cost of overall treatment. Moreover, the drugs which are currently used for the treatment of UAB are not proven to satisfy clinically from the viewpoint of effectiveness and safety, which leads to the requirement for new therapeutic agents to develop.

Middle East and Africa underactive bladder market is expected to grow in the forecast period due to the rise in market players and the presence of novel pipeline drugs. Along with this, manufacturers are engaged in R&D activities for launching novel products in the market.

However, the high cost associated with the research and studies is expected to restrain market growth which can further impact the launch of new products in the market.

The increase in the number of R&D programs, and the rise in public-private partnerships for facilitating novel developments for innovative and effective treatment further influence the market.

Middle East and Africa underactive bladder market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various regions and partnership with suppliers for safe distribution of machine and drugs products are the major drivers which propelled the demand of the market in the forecast period.

Middle East and Africa underactive bladder market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyzes that Middle East and Africa underactive bladder market will grow at a CAGR of 3.5% during the forecast period of 2022 to 2029.

Market Definition

Underactive bladder (UAB) is a clinical condition in which urination disorder is developed as a result of the reduction in the contraction of a detrusor muscle (a detrusor muscle of the bladder) during urination. It is characterized by the feeling of having to urinate immediately, and thus, this condition is different from overactive bladder. The present invention provides a pharmaceutical composition useful for the prevention or treatment of UAB which has an effect of improving the urinary flow rate, an effect of improving the over distension of the bladder (an effect of reducing bladder capacity), and is therefore useful for the prevention or treatment of UAB.

Moreover, it is a disease state which is different from the overactive bladder characterized by urinary urgency which has been attracting attention in recent years. Causes of UAB include autonomic neuropathy such as diabetes and alcoholism, pelvic surgery such as radical hysterectomy and radical rectal cancer, spinal cord diseases such as spina bifida, and disc herniation is also known. Patients suffering from severe and mild bladder disorder associated problems needs pharmacotherapy often cycle with multiple therapies and without adequate relief receiving continue treatments, which also creates an impact on healthcare expenditure.

Middle East and Africa Underactive Bladder Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of these are discussed in detail below:

Drivers

• Increasing prevalence of neurological disorder

UAB is a common neurological condition in which nerves and muscles do not work together very well resulting in prolonged urination time with or without a sensation of incomplete bladder emptying. In this condition, the detrusor muscles underperform for their contraction activity which is characterized by a slow urinary stream, hesitancy, and straining to void, with or without a feeling of incomplete bladder emptying, sometimes with storage symptoms even. Thus, the bladder either does not empty or empties only partially which is due to the bladder muscles being unable to release urine properly.

As a result, patients with UAB may have various urination symptoms and may be accompanied by a large amount of residual urine. Complications of urinary retention due to aggravation and Urinary Tract Infections (UTIs) due to chronic residual urine are often seen and have become a problem. Moreover, it is a disease state which is different from the OAB characterized by urinary urgency which has been attracting attention in recent years. Thus, the increasing prevalence of neurogenic bladder disorders is expected to drive market growth. This will lead to an increased demand for treatment that can detect patients as well, due to which there will be expected lucrative growth in the market.

• Rising health care expenditure

The instruments, manpower, and medical management in case of any harm to researchers, insurance, transportation, ethics committee fee, data processing, and other consumables lead to major cost involvement for the market players. The healthcare expenditure comprises all healthcare services, testing devices, family planning activities, and emergency aid designated for health. National Health Accounts provide many indicators based on expenditure collected within an internationally recognized framework. The factors determining any country's healthcare expenditure are income (per capita GDP), technological progress and variation in medical practice, and health systems characteristics.

The rise in healthcare expenditure simultaneously helps healthcare organizations and government bodies increase the research activities on menopause drugs, their upcoming clinical trials, and R&D activities. Also, the cost involved in the production and manufacturing of the new products, the market players require adequate allocation of funds and resources, hence, the government acts as a helping hand in this scenario. Growing healthcare expenditure is also beneficial for further economic development and growth of the healthcare sector. In addition, the increase in disposable income of the population is a favorable factor. Hence, rising healthcare expenditure is expected to drive market growth in the future.

Opportunity

•  Rising urologic complications of diabetes

One of the known causes of UAB includes autonomic neuropathy such as diabetes. Moreover, diabetes is associated with an earlier onset and increased severity of urologic diseases that result in costly and debilitated urologic complications. These urologic complications, including bladder dysfunction and UTIs among others, have a profound effect on the quality of life of both men and women with diabetes. Diabetes and urologic diseases are very common health problems that markedly increase in prevalence and incidence with advancing age. Urologic complications of diabetes are an immediate effect. Diabetes is the most prominent disorder and has a high prevalence globally.

Diabetes-associated bladder complications can be due to an alternation in the detrusor smooth muscles, neuronal dysfunction, and urothelial dysfunction. Depending on the nerves involved, the effects of diabetic neuropathy can range from discomfort and numbness in the legs to complications with the digestive system, the urinary tract, the blood vessels, and the core. The rising data on diabetes will significantly increase the risk of urologic complications of diabetes worldwide. Thus, it is required to recommend future directions for research and clinical care for proper treatment of urologic complications of diabetes. Support from other organizations would also be required to reach the under-developed regions to tackle the neglected complications. Therefore, this signifies that the rise in urologic complications of diabetes is expected to act as an opportunity for market growth.

Restraint/Challenge

• High cost of Research and Development (R&D)

R&D is a prerequisite in modifying the procedure intended to treat different kinds of patients. The higher cost of R&D for new products demands deep research and clinical studies. The various clinical phases in R&D require huge investments which can affect market growth. The research cost involved in planning and execution of the studies, and research requires adequate allocation of funds and resources, which can affect new developments in the market. The cost of the product plays a major factor in the market. Many diagnostic options are available in the market, but due to their high cost, most people tend to avoid going for a diagnosis. Diagnostic approaches have come with greater sensitivity and specificity cost of the test also increased.

The high cost of the procedure is due to various checkpoints of treatments along with the use of high-tech modalities to perform such procedures. As cost of R&D for treatments is too high, it restricts accommodating high-quality and effective solutions. Henceforth, the high cost negatively impacts the cost of overall treatment. Consequently, it will constrict the future demand for treatment in low and middle-income countries. This suggests that the high cost associated with the research and studies is expected to restrain market growth which can further impact the launch of new products in the market.

Post COVID-19 Impact on Middle East and Africa Underactive Bladder Market

COVID-19 has positively affected in the growth of the market as there is rise in the demand for products widely in the region. People have become more health conscious as there is rising prevalence of various bladder diseases in the region. Complications of urinary retention due to aggravation and UTIs due to chronic residual urine are often seen and have become a problem. Hence, COVID-19 has impacted positively on this market.

Recent Developments

• In June 2020, Vesiflo, Inc. announced the medicare coverage of inFlow urinary prosthesis, a magnetically coupled FDA-approved intraurethral valve-pump device which can be used for 29 days by adult women as an alternative to intermittent catheterization. This results in a contribution to the expansion of product business quickly with commercialization in the market.
• In April 2020, Astellas Pharma Europe Ltd. completed a clinical trial that was conducted on subjects for the treatment of underactive bladder. Currently, ASP8302 is under phase-2 clinical trial to investigate the safety and tolerability of the drug in patients with underactive bladder.

Middle East and Africa Underactive Bladder Market Scope

Middle East and Africa underactive bladder market is categorized into four notable segments based on type, route of administration, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Type

• Pharmacotherapy
• Surgical Methods
• Urethral Assist Device
• Stem Cell and Gene Therapies

Based on type, the market is segmented into pharmacotherapy, surgical methods, urethral assist device, and stem cell and gene therapies.

Route of Administration

• Oral
• Parenteral
• Others

Based on route of administration, the market is segmented into oral, parenteral, and others.

End User

• Hospitals
• Clinics
• Academic and Research Institutes
• Others

Based on end user, the market is segmented into hospitals, clinics, academic and research institutes, and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

Based on distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and others.

Middle East and Africa Underactive Bladder Market Regional Analysis/Insights

Middle East and Africa underactive bladder market is analyzed and market size insights and trends are provided by type, route of administration, end user, and distribution channel as referenced above.

The countries covered in the Middle East and Africa underactive bladder market report are Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, and rest of Middle East and Africa.

In 2022, Middle East and Africa underactive bladder market is expected to grow due to the increasing prevalence of bladder disorders and growing geriatric population. The technological advances for the treatment of bladder disorders and the rise in product approvals are also boosting market growth.

South Africa is expected to dominate due to the presence of big market players and an established healthcare system to treat bladder disorders.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Middle East and Africa Underactive Bladder Market Share Analysis

Middle East and Africa underactive bladder market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the Middle East and Africa underactive bladder market.

Some players in the market are

• Astellas Pharma Inc.
• Aurobindo Pharma.
• Boehringer Ingelheim International GmbH
• Macleods Pharmaceuticals Ltd.
• Orion Corporation
• Novartis AG
• Pfizer Inc.
• Cipla Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Almirall, S.A
• Alkem Labs.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Middle East and Africa vs country, and Vendor Share Analysis. Please request analyst call in case of further inquiry.

SKU-69096